Analysis of the clinical pipeline of treatments for drug resistant bacterial infections: despite progress, more action is needed.
There is an urgent global need for new strategies and drugs to control and treat multi-drug resistant bacterial infections. In 2017, the World Health Organization (WHO) released a list of 12 antibiotic-resistant priority pathogens and began to critically analyze the antibacterial clinical pipeline....
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
American Society for Microbiology
2022
|
| _version_ | 1797106647980572672 |
|---|---|
| author | Butler, MS Gigante, V Sati, H Paulin, S Al-Sulaiman, L Rex, JH Fernandes, P Arias, CA Paul, M Thwaites, GE Czaplewski, L Alm, RA Lienhardt, C Spigelman, M Silver, LL Ohmagari, N Kozlov, R Harbarth, S Beyer, P |
| author_facet | Butler, MS Gigante, V Sati, H Paulin, S Al-Sulaiman, L Rex, JH Fernandes, P Arias, CA Paul, M Thwaites, GE Czaplewski, L Alm, RA Lienhardt, C Spigelman, M Silver, LL Ohmagari, N Kozlov, R Harbarth, S Beyer, P |
| author_sort | Butler, MS |
| collection | OXFORD |
| description | There is an urgent global need for new strategies and drugs to control and treat multi-drug resistant bacterial infections. In 2017, the World Health Organization (WHO) released a list of 12 antibiotic-resistant priority pathogens and began to critically analyze the antibacterial clinical pipeline. This review analyzes 'traditional' and 'non-traditional' antibacterial agents and modulators in clinical development current on 30 June 2021 with activity against the WHO priority pathogens, mycobacteria and Clostridioides difficile. Since 2017, 12 new antibacterial drugs have been approved globally, but only vaborbactam belongs to a new antibacterial class. Also innovative is the cephalosporin derivative cefiderocol, which incorporates an iron-chelating siderophore that facilitates Gram-negative bacteria cell entry. Overall, there were 76 antibacterial agents in clinical development (45 traditional and 31 non-traditional) with 28 in Phase 1, 32 in Phase 2, 12 in Phase 3 and four under regulatory evaluation. Forty-one out of 76 (54%) targeted WHO priority pathogens, 16 (21%) against mycobacteria, 15 (20%) against C. difficile and 4 (5%) are non-traditional agents with broad spectrum effects. Nineteen of the 76 antibacterial agents have new pharmacophores and four of these have new modes of actions not previously exploited by marketed antibacterial drugs. Despite there being 76 antibacterial clinical candidates, this analysis indicated that there were still relatively few clinically differentiated antibacterial agents in late-stage clinical development, especially against critical Priority Pathogens. We believe that future antibacterial R&D should focus on the development of innovative and clinically differentiated candidates that have clear and feasible progression pathways to the market. |
| first_indexed | 2024-03-07T07:05:31Z |
| format | Journal article |
| id | oxford-uuid:f212f5d2-27cf-449f-ad56-a21f0c24492d |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:05:31Z |
| publishDate | 2022 |
| publisher | American Society for Microbiology |
| record_format | dspace |
| spelling | oxford-uuid:f212f5d2-27cf-449f-ad56-a21f0c24492d2022-04-19T17:30:17ZAnalysis of the clinical pipeline of treatments for drug resistant bacterial infections: despite progress, more action is needed.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:f212f5d2-27cf-449f-ad56-a21f0c24492dEnglishSymplectic ElementsAmerican Society for Microbiology2022Butler, MSGigante, VSati, HPaulin, SAl-Sulaiman, LRex, JHFernandes, PArias, CAPaul, MThwaites, GECzaplewski, LAlm, RALienhardt, CSpigelman, MSilver, LLOhmagari, NKozlov, RHarbarth, SBeyer, PThere is an urgent global need for new strategies and drugs to control and treat multi-drug resistant bacterial infections. In 2017, the World Health Organization (WHO) released a list of 12 antibiotic-resistant priority pathogens and began to critically analyze the antibacterial clinical pipeline. This review analyzes 'traditional' and 'non-traditional' antibacterial agents and modulators in clinical development current on 30 June 2021 with activity against the WHO priority pathogens, mycobacteria and Clostridioides difficile. Since 2017, 12 new antibacterial drugs have been approved globally, but only vaborbactam belongs to a new antibacterial class. Also innovative is the cephalosporin derivative cefiderocol, which incorporates an iron-chelating siderophore that facilitates Gram-negative bacteria cell entry. Overall, there were 76 antibacterial agents in clinical development (45 traditional and 31 non-traditional) with 28 in Phase 1, 32 in Phase 2, 12 in Phase 3 and four under regulatory evaluation. Forty-one out of 76 (54%) targeted WHO priority pathogens, 16 (21%) against mycobacteria, 15 (20%) against C. difficile and 4 (5%) are non-traditional agents with broad spectrum effects. Nineteen of the 76 antibacterial agents have new pharmacophores and four of these have new modes of actions not previously exploited by marketed antibacterial drugs. Despite there being 76 antibacterial clinical candidates, this analysis indicated that there were still relatively few clinically differentiated antibacterial agents in late-stage clinical development, especially against critical Priority Pathogens. We believe that future antibacterial R&D should focus on the development of innovative and clinically differentiated candidates that have clear and feasible progression pathways to the market. |
| spellingShingle | Butler, MS Gigante, V Sati, H Paulin, S Al-Sulaiman, L Rex, JH Fernandes, P Arias, CA Paul, M Thwaites, GE Czaplewski, L Alm, RA Lienhardt, C Spigelman, M Silver, LL Ohmagari, N Kozlov, R Harbarth, S Beyer, P Analysis of the clinical pipeline of treatments for drug resistant bacterial infections: despite progress, more action is needed. |
| title | Analysis of the clinical pipeline of treatments for drug resistant bacterial infections: despite progress, more action is needed. |
| title_full | Analysis of the clinical pipeline of treatments for drug resistant bacterial infections: despite progress, more action is needed. |
| title_fullStr | Analysis of the clinical pipeline of treatments for drug resistant bacterial infections: despite progress, more action is needed. |
| title_full_unstemmed | Analysis of the clinical pipeline of treatments for drug resistant bacterial infections: despite progress, more action is needed. |
| title_short | Analysis of the clinical pipeline of treatments for drug resistant bacterial infections: despite progress, more action is needed. |
| title_sort | analysis of the clinical pipeline of treatments for drug resistant bacterial infections despite progress more action is needed |
| work_keys_str_mv | AT butlerms analysisoftheclinicalpipelineoftreatmentsfordrugresistantbacterialinfectionsdespiteprogressmoreactionisneeded AT gigantev analysisoftheclinicalpipelineoftreatmentsfordrugresistantbacterialinfectionsdespiteprogressmoreactionisneeded AT satih analysisoftheclinicalpipelineoftreatmentsfordrugresistantbacterialinfectionsdespiteprogressmoreactionisneeded AT paulins analysisoftheclinicalpipelineoftreatmentsfordrugresistantbacterialinfectionsdespiteprogressmoreactionisneeded AT alsulaimanl analysisoftheclinicalpipelineoftreatmentsfordrugresistantbacterialinfectionsdespiteprogressmoreactionisneeded AT rexjh analysisoftheclinicalpipelineoftreatmentsfordrugresistantbacterialinfectionsdespiteprogressmoreactionisneeded AT fernandesp analysisoftheclinicalpipelineoftreatmentsfordrugresistantbacterialinfectionsdespiteprogressmoreactionisneeded AT ariasca analysisoftheclinicalpipelineoftreatmentsfordrugresistantbacterialinfectionsdespiteprogressmoreactionisneeded AT paulm analysisoftheclinicalpipelineoftreatmentsfordrugresistantbacterialinfectionsdespiteprogressmoreactionisneeded AT thwaitesge analysisoftheclinicalpipelineoftreatmentsfordrugresistantbacterialinfectionsdespiteprogressmoreactionisneeded AT czaplewskil analysisoftheclinicalpipelineoftreatmentsfordrugresistantbacterialinfectionsdespiteprogressmoreactionisneeded AT almra analysisoftheclinicalpipelineoftreatmentsfordrugresistantbacterialinfectionsdespiteprogressmoreactionisneeded AT lienhardtc analysisoftheclinicalpipelineoftreatmentsfordrugresistantbacterialinfectionsdespiteprogressmoreactionisneeded AT spigelmanm analysisoftheclinicalpipelineoftreatmentsfordrugresistantbacterialinfectionsdespiteprogressmoreactionisneeded AT silverll analysisoftheclinicalpipelineoftreatmentsfordrugresistantbacterialinfectionsdespiteprogressmoreactionisneeded AT ohmagarin analysisoftheclinicalpipelineoftreatmentsfordrugresistantbacterialinfectionsdespiteprogressmoreactionisneeded AT kozlovr analysisoftheclinicalpipelineoftreatmentsfordrugresistantbacterialinfectionsdespiteprogressmoreactionisneeded AT harbarths analysisoftheclinicalpipelineoftreatmentsfordrugresistantbacterialinfectionsdespiteprogressmoreactionisneeded AT beyerp analysisoftheclinicalpipelineoftreatmentsfordrugresistantbacterialinfectionsdespiteprogressmoreactionisneeded |